<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>PRO Alert Digest</title>
  <style>
    body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif; margin: 2rem; color: #222; }
    header { margin-bottom: 2rem; }
    section { margin-bottom: 2rem; background: #f5f5f5; padding: 1rem; border-radius: 0.5rem; }
    section h2 { margin-top: 0; font-size: 1.1rem; color: #333; }
    section ul { margin-bottom: 0; }
    article { margin-bottom: 2rem; }
    article h2 { margin-bottom: 0.5rem; font-size: 1.25rem; }
    article ul { margin-top: 0.5rem; }
    article li strong { color: #0066cc; }
    .meta { color: #666; font-size: 0.9rem; margin: 0; }
  </style>
</head>
<body>
<header><h1>PRO Alert Digest</h1><p>October 13, 2025</p></header>
<section class="summary">
  <h2>Summary of today's articles</h2>
  <ul>
    <li>Over 60% of oncology practices struggle to capture electronic Patient-Reported Outcomes (**PROs**) effectively, highlighting a critical gap in clinical data...</li>
    <li>PROs provide holistic evaluation of treatment impact; EQ-5D-5 L and MLHFQ predict all-cause mortality in ATTR-CM.</li>
    <li>Patient-reported outcomes (PROs) in kidney cancer can predict survival and treatment response, with **70%** accuracy in clinical trials.</li>
  </ul>
</section>

<section class="insights">
  <h2>ðŸ“Š Cross-Article Insights</h2>
  <ul>
    <li>PATTERN: Clinical Validity mentioned 8x across articles</li>
    <li>PATTERN: Implementation mentioned 5x across articles</li>
    <li>PATTERN: Technology mentioned 5x across articles</li>
    <li>CLINICAL VALIDITY: Multiple articles support PROs as outcome predictors</li>
  </ul>
</section>

<article>
  <h2><a href="https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391">Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> Over 60% of oncology practices struggle to capture electronic Patient-Reported Outcomes (**PROs**) effectively, highlighting a critical gap in clinical data collection and patient engagement.</li>
<li>**TACTICAL WIN** [SHIP NOW]: Implement AI-driven interfaces for PROs that simplify data entry for patients while ensuring high compliance rates among oncology patients.</li>
<li>**MARKET SIGNAL** ðŸ”´ URGENT: With FDA guidelines tightening on digital health tools, early adopters of robust PRO platforms could gain a competitive edge in the rapidly evolving oncology tech market.</li>
<li><strong>CONCERN:</strong> The current lack of standardized PRO metrics poses a challenge for cross-study comparability, potentially undermining the clinical validity of emerging oncology treatments.</li>
  </ul>
</article>
<article>
  <h2><a href="https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204">Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> PROs provide holistic evaluation of treatment impact; EQ-5D-5 L and MLHFQ predict all-cause mortality in ATTR-CM.</li>
<li><strong>TACTICAL WIN:</strong> [SHIP NOW] Implement ePRO solutions with validated questionnaires (KCCQ, NYHA) for real-time patient monitoring and decision-making.</li>
<li><strong>MARKET SIGNAL:</strong> ðŸ”´ URGENT - FDA approval trends favor PRO-based endpoints; competitors may adopt similar strategies.</li>
<li><strong>CONCERN:</strong> âš« CONTEXT - Inconsistent PRO outcomes vs clinical results; caution needed in interpreting trial data.</li>
  </ul>
</article>
<article>
  <h2><a href="https://ascopubs.org/doi/10.1200/OA-25-00051">Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> Patient-reported outcomes (PROs) in kidney cancer can predict survival and treatment response, with **70%** accuracy in clinical trials.</li>
<li><strong>TACTICAL WIN:</strong> [SHIP NOW] Integrate real-time PRO dashboards for immediate patient feedback on symptom management.</li>
<li><strong>MARKET SIGNAL:</strong> The global PRO market is projected to grow by **15% annually**, driven by personalized medicine trends and reimbursement policies favoring PRO-informed care. ðŸš€ WATCH</li>
<li><strong>CONCERN:</strong> Challenges include ensuring PRO data quality and integrating diverse PROs into clinical workflows, which may lead to inconsistencies in **implementation** across healthcare systems. âš« CONTEXT</li>
  </ul>
</article>

</body>
</html>
